Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai No 1 Pharmacy Co's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 36.63.
Shanghai No 1 Pharmacy Co's Days Inventory for the
three
months ended in Mar. 2026 was 79.59.
Shanghai No 1 Pharmacy Co's Days Payable for the
three
months ended in Mar. 2026 was 102.
Therefore, Shanghai No 1 Pharmacy Co's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 14.22.
Shanghai No 1 Pharmacy Co (SHSE:600833) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Shanghai No 1 Pharmacy Co Cash Conversion Cycle Related Terms
Shanghai No 1 Pharmacy Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai No 1 Pharmacy Co Cash Conversion Cycle Chart
Shanghai No 1 Pharmacy Co Cash Conversion Cycle Competitor Comparison
For the Pharmaceutical Retailers subindustry, Shanghai No 1 Pharmacy Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai No 1 Pharmacy Co Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Shanghai No 1 Pharmacy Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Shanghai No 1 Pharmacy Co's Cash Conversion Cycle falls into.
Shanghai No 1 Pharmacy Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Shanghai No 1 Pharmacy Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai No 1 Pharmacy Co (SHSE:600833) has a Cash Conversion Cycle of 14.22 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shanghai No 1 Pharmacy Co and its competitors.
Is Shanghai No 1 Pharmacy Co's Cash Conversion Cycle too high?
Shanghai No 1 Pharmacy Co's current Cash Conversion Cycle is 14.22. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.83. Shanghai No 1 Pharmacy Co's value of 14.22 is 20.2% below this industry median. Overall, Shanghai No 1 Pharmacy Co has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai No 1 Pharmacy Co's Cash Conversion Cycle compare to competitors?
Shanghai No 1 Pharmacy Co's Cash Conversion Cycle of 14.22 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.83. Shanghai No 1 Pharmacy Co's value of 14.22 is 20.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.83, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai No 1 Pharmacy Co's current Cash Conversion Cycle of 14.22 is 20.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Shanghai No 1 Pharmacy Co and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai No 1 Pharmacy Co's current Cash Conversion Cycle is 14.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai No 1 Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai No 1 Pharmacy Co (SHSE:600833) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.83, compared to a current price of ¥9.48 — trading 26.1% below its estimated fair value. The current Cash Conversion Cycle is 14.22 and 20.2% below the Healthcare Providers & Services industry median of 17.83. Shanghai No 1 Pharmacy Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Shanghai No 1 Pharmacy Co (SHSE:600833), the current Cash Conversion Cycle is 14.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai No 1 Pharmacy Co (SHSE:600833) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai No 1 Pharmacy Co stock appears to be undervalued.
The current stock price of ¥9.48 is trading 26.1% below its estimated GF Value™ of ¥12.83.
GuruFocus considers Shanghai No 1 Pharmacy Co to be Modestly Undervalued.
Key valuation signals for SHSE:600833:
Cash Conversion Cycle: 14.22
GF Value™: ¥12.83 vs. price of ¥9.48 (26.1% below fair value)
Industry Position: 20.2% below the Healthcare Providers & Services median
No single metric tells the full story. See the SHSE:600833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai No 1 Pharmacy Co Ltd is engaged in pharmaceutical retail and wholesale in China. The company's product profile include Lei Shi Pearl Powder, Tongrentang Ejiao Powder, Wanshuntang Yangyin mouth fragrance mixture, and others. It also provides Nourishing health Nutrition, Medical instruments, Rehabilitation care, Contact lens, and others.
56GF Score
Get the complete analysis for SHSE:600833
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600833 has been successfully added to your 
